Weight loss jab Wegovy could lower your risk of dementia
Researchers found these medications show promise in lowering the risk of cognitive impairment.
Experts say further research is needed to understand the drugs' effects on the brain and the mechanisms behind this potential protective effect.
The US study analysed data from type 2 diabetes patients taking either GLP-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2inhibitors (SGLT-2i).
GLP-1RAs like semaglutide work by suppressing appetite, while SGLT-2i reduce glucose reabsorption in the kidneys.
Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets.
The study's findings indicate a potential link between these medications and a lower risk of dementia.
Wegovy was approved to tackle weight loss on the NHS in 2023, while Ozempic and Rybelus are available on the health service as treatments for type 2 diabetes.
The study examined the health records of 396,963 people from the OneFlorida+ Clinical Research Consortium between January 2014 and June 2023.
All patients were aged over 50 and had type 2 diabetes. They had no diagnosis of Alzheimer's disease and related dementias (ADRD).
Researchers compared those on GLP-1RAs, SGLT-2i and other, second-line glucose-lowering drugs.
The analysis found that 'both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs'.
Meanwhile, among the GLP-1RAs, 'semaglutide seems to be promising in reducing the risk of ADRD'.
'This finding is particularly intriguing given the existing research on semaglutide's neuroprotective properties,' researchers said.
Dr Leah Mursaleen, head of clinical research at Alzheimer's Research UK, said: 'The results from this study support the growing evidence that GLP-1RA and SGLT-2 inhibitors medicines may reduce dementia risk.
'We don't know yet why these medicines may be offering a protective effect, and will need more research to understand how they are affecting the brain.'
She added that while the findings are 'interesting', it is important to consider if other factors might be influencing results like overall health, income or education.
Meanwhile, researchers in Ireland suggested GLP-1RAs are 'associated with a statistically significant reduction in dementia'.
The study analysed 26 clinical trials involving almost 165,000 patients to determine if drugs like SGLT2is and GLP-1RAs, as well as diabetes medications metformin and pioglitazone, led to a reduction in risk of dementia or cognitive impairment.
It found most drugs 'were not associated with an overall reduction in all-cause dementia' although 'GLP-1RAs was associated with a statistically significant reduction in all-cause dementia'.
Both studies have been published in the journal Jama Neurology.
Prof Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh, group leader in the UK Dementia Research Institute, and president of the British Neuroscience Association, said the data is 'encouraging' for the 'potential of using GLP-1Ras to lower dementia risk in people with diabetes'
'But even within these two strong studies, there are slightly conflicting results over SGLT2is highlighting the need for further research,' she added.
'It is important to note that these drugs do have side effects and that they are not guaranteed to prevent dementia.
'The studies had important limitations including a relatively short follow up time. Future work will be important to understand how risk factors like diabetes and obesity increase risk of dementia to develop effective treatments and prevention strategies.'
Masud Husain, a professor of neurology and cognitive neuroscience at the University of Oxford, added: 'For me, these new retrospective analyses suggest that GLP-1 receptor agonists, particularly semaglutide, might reduce the risk of developing dementia in people with type 2 diabetes.
'But we need data from prospective trials to provide stronger evidence.
'The wider question of whether such drugs might also be protective against dementia in people who don't have diabetes is a really intriguing one, and the focus of several ongoing clinical trials.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
35 minutes ago
- The Independent
Pricing people out of using Mounjaro would be bad news for the NHS
There were scenes of shock in pharmacies across the country when a notice from pharmaceutical giant Eli Lilly hit inboxes out of nowhere last week. The wholesale price of their popular weight-loss drug Mounjaro, administered via jabs, was going to more than double from the start of September. While Eli Lilly has struck an, as yet secret, deal with the NHS, this massive increase will hit the vast majority of patients who are prescribed Mounjaro privately. More than a million Britons are estimated to already be taking Mounjaro, and scores more are interested in using it to start their weight-loss journey. So, when the news of this massive price hike went public, it wasn't only pharmacists who were worried and disappointed. The first message to concerned patients is don't panic and don't stop taking your medication; your local pharmacy is ready and willing to talk you through the options going forward. There are alternatives to Mounjaro that, for now at least, remain cheaper. They may be right for you, but it is essential that you get professional advice before you do anything, and your neighbourhood pharmacist is best placed and most on hand to give that advice. The consequences of this unprecedented price hike won't just hit patients; they will also hit the pharmacies on Britain's high streets. The finances of the whole pharmacy sector are already in a state of crisis after years of underfunding. The price hike for Mounjaro will put it under more financial strain. Unless the government steps in and offers the sector a fairer funding settlement for our NHS work, then, inevitably, we are going to see more pharmacies close and more communities robbed of the vital service on their street corner. If the government really wants pharmacies to be the 'front door' of their Neighbourhood Health Service, then it needs to act now. We call on the other weight-loss manufacturers to hold their nerve and hold their prices. The British market for weight-loss jabs was only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient. There is a real danger that patients priced out of Mounjaro, but anxious to maintain treatment, turn to sourcing replacements online. If other manufacturers follow suit and up their prices, that danger will only grow. In their desperation, patients could well end up sourcing counterfeit jabs online, which are completely unregulated and potentially extremely harmful. At the click of a mouse, patients can find themselves buying jabs that they have no idea what they contain, or if they were manufactured in safe conditions, no matter what picture the unscrupulous sites use to tempt them in. We are urging patients to be extremely cautious and vigilant when looking to buy weight loss medication online. If it looks too good to be true, it almost certainly is. Again, talk to your trained and regulated community pharmacy, which is there to help. There is a real risk it won't end here. Although the companies would deny it, tariffs and the noise from the White House would seem to be hitting this side of the Atlantic. British patients must not become pawns in a wider dispute about the costs of medicines arising from President Trump's recent letter to the US drug manufacturers. For now, it seems that weight-loss jabs prescribed privately are the easy win for the pharma giants, but we are concerned that more companies may increase the prices of more medicines as a result of tariffs. Any increases in wholesale prices, even for those drugs prescribed by the NHS, will impact the sustainability of the sector. The Mounjaro price hike came out of the blue. It could prove just the start. Exploding prices for pharmaceuticals risks a genuine and rapid crisis. Ministers need to urgently develop contingency plans; otherwise, we risk the system that keeps vital medicines flowing to patients entering an unprecedented era of uncertainty.
Daily Record
2 hours ago
- Daily Record
GP explains difference between ‘chronic fatigue' signs and normal burnout
Chronic Fatigue Syndrome symptoms and general burnout can be hard to tell apart, but one GP is highlighting the difference Chronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis, is a complex and long-term condition that can severely impact a person's daily life. However, it can be hard to diagnose as the symptoms often overlap and mimic a range of other issues like general burnout or sleep disorders. There's no single way of treating CFS, it's all individually tailored to each person's symptoms according to the NHS so getting a speedy diagnosis is vital to address the issues impacting your daily life. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, highlighted the few signs that set CFS apart. He said: 'While burnout and CFS share some common symptoms, they can also be incredibly different. Understanding the contrasts can allow people to identify chronic fatigue more effectively. 'Typically, feelings of burnout are brought on through excessive stress, almost always tied to a particular event such as work. Burnout can be treated through rest and addressing the issues that cause overwhelming stress. 'On the other hand, CFS is a long-term condition that isn't relieved through sleep, recovery or addressing potential stressors. Instead, the body can feel like it's run a marathon, even after the smallest of tasks. While burnout is generally psychological, CFS can impact the body on a physical level.' Certain factors can also heighten your chances of developing CFS or make the symptoms worse, including the menopause, mental health problems, long Covid and other viral infections. However, the main culprit is typically sleep troubles such as insomnia or being unable to maintain a regular sleep pattern that delivers seven to nine hours of rest nightly. The GP continued: 'Other signs of CFS include changes to cognitive function such as difficulty with memory, concentration or general brain fog. 'It's also common for people with CFS to feel worn out after completing simple tasks, while also experiencing joint and muscle pain, without necessarily putting their bodies through any physical exertion.' Plenty of people might encounter one or two of these symptoms occasionally, or even struggle with burnout and general exhaustion. However, the GP encouraged people to discuss these concerns openly with their doctor as there's currently no specific method to diagnose CFS and highlighting your symptoms can result in a swifter and more precise diagnosis. He continued: 'GPs will generally ask about lifestyle habits and potential stressors while assessing prior medical history to identify potential causes of decreasing energy levels. Like the diagnosis process, there's no specific way to treat CFS. 'Instead, doctors will trial a few different approaches. This includes cognitive behaviour therapy (CBT) and incorporating methods for energy management into people's daily routines. 'Also, as CFS can impact sleep or physical pain, a GP might prescribe medications that can target and lower the intensity of these symptoms. Overall, I believe CFS can be complicated to identify, for both medical professionals and potential sufferers. However, by understanding the tell-tale signs and how it differs from burnout or general tiredness, spotting CFS can be made so much easier.'
Telegraph
2 hours ago
- Telegraph
Private school pupils ‘barred' from work experience at NHS hospitals
Private school pupils have been 'barred' from undertaking work experience at some of the largest NHS hospital trusts. Official schemes at world-famous London hospitals, including Barts and University College London Hospital (UCLH) are reportedly only open to children from local state schools. The doctors' trade union, the British Medical Association (BMA), advises children considering a career in medicine that they need clinical work experience to even be considered for a university medical course. One would-be medical student from Emanuel School in south London was told by King's College Hospital Trust – their local NHS trust – that pupils from private schools were not admitted onto their courses, even if they lived in the area, the Mail on Sunday reported. War on private schools It comes amid Labour's ongoing war against private schools, which has disrupted the education of thousands of children across the country amid a wave of sudden closures. Rachel Reeves, the Chancellor, imposed a 20 per cent tax on private school fees in January, making them subject to VAT for the first time. Pupil numbers have since dropped four times faster than government forecasts predicted, suggesting the move has backfired. Around £200m in VAT has also failed to materialise, while taxpayers must now find an extra £90m per year to cover the costs of displaced private pupils flooding into state schools. Critics say Labour is trying to punish the children of its perceived opponents as a way of courting Left-wing voters who cannot afford private education for their offspring. Others point out that forcing children of parents who cannot afford its tax hikes into a scramble for school places within the under-pressure public sector is cruel and disruptive. Children on bursaries shut out Gordon West, the head of careers at Stowe, a prestigious independent school, revealed that a pupil of his had been unable to secure medical work experience. 'This young woman is not from a wealthy background at all; she's from one of the highest priority groups there are,' he said. 'Policies like [those of] King's College don't account for stories like hers. By excluding private school kids, they also shut out students on 100 per cent bursaries, many of whom come from families with very limited means.' The pupil in question is understood to be on a 100 per cent bursary, which is granted to children whose parents could otherwise not afford to send their academically able offspring to private schools. A King's College Hospital NHS Trust spokesman told the Mail on Sunday: 'In 2024, we facilitated 396 work placements. The vast majority were for students from state schools.' At Barts Hospital, a spokesman told the newspaper that placements for private school pupils were available, but only if a member of staff referred the children in question. On its website, UCLH said it would not accept work experience students outside of its partnerships with The Social Mobility Foundation and 'selected local schools'. A spokesman reportedly said that placements could be arranged 'for friends and family of UCLH staff members'.
